INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26201, 27250, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26202, 28356, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26203, 28357, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26204, 28823, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26205, 29195, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26206, 29196, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26207, 2944, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26208, 4825, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26209, 4995, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26210, 9310, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26211, 10632, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26212, 10633, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26213, 13015, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26214, 13016, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26215, 20758, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26216, 20759, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26217, 23243, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26218, 23244, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26219, 27094, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26220, 27214, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26221, 27249, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26222, 27250, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26223, 28356, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26224, 28357, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26225, 28823, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26226, 29195, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26227, 29196, 'Solifenacin', 'Kidney Failure, Chronic', 'Solifenacin should be used with caution in patients with renal impairment.  Increase in half-life and AUC have been demonstrated in patients with severe renal impairment.  Caution should be taken when prescribing this agent to patients with renal impairment.  Doses greater than 5 mg in patients with severe renal impairment is not recommended by the manufacturer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26228, 2944, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26229, 4825, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26230, 4995, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26231, 9310, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26232, 10632, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26233, 10633, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26234, 13015, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26235, 13016, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26236, 20758, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26237, 20759, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26238, 23243, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26239, 23244, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26240, 27094, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26241, 27214, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26242, 27249, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26243, 27250, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26244, 28356, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26245, 28357, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26246, 28823, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26247, 29195, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26248, 29196, 'Solifenacin', 'Liver Failure', 'Solifenacin should be used with caution in patients with reduced hepatic function.  Increase in half-life and AUC have been demonstrated in patients with reduce hepatic impairment.  Caution should be taken when prescribing this agent to patients with moderate hepatic impairment and the use of doses greater than 5 mg in these patients is not recommended by the manufacturer.  Solifenacin is not recommended in patients with severe hepatic impairment.  .', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26249, 2944, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26250, 4825, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26251, 4995, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26252, 9310, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26253, 10632, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26254, 10633, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26255, 13015, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26256, 13016, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26257, 20758, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26258, 20759, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26259, 23243, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26260, 23244, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26261, 27094, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26262, 27214, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26263, 27249, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26264, 27250, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26265, 28356, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26266, 28357, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26267, 28823, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26268, 29195, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26269, 29196, 'Solifenacin', 'Glaucoma, Angle-Closure', 'The use of solifenacin is contraindicated in patients with uncontrolled narrow-angle glaucoma.  Caution is advised even when using this agent in patients with narrow-angle glaucoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26270, 2944, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26271, 4825, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26272, 4995, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26273, 9310, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26274, 10632, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26275, 10633, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26276, 13015, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26277, 13016, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26278, 20758, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26279, 20759, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26280, 23243, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26281, 23244, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26282, 27094, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26283, 27214, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26284, 27249, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26285, 27250, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26286, 28356, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26287, 28357, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26288, 28823, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26289, 29195, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26290, 29196, 'Solifenacin', 'Urethral Obstruction', 'The use of solifenacin is contraindicated in patients with urinary retention.  Caution is advised even when using this agent in patients with clinically significant bladder outflow obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26291, 2944, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26292, 4825, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26293, 4995, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26294, 9310, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26295, 10632, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26296, 10633, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26297, 13015, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26298, 13016, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26299, 20758, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26300, 20759, 'Solifenacin', 'Central Nervous System Diseases', 'Solifenacin is associated with anticholinergic central nervous system (CNS) effects.  Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose.  If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.  Solifenacin should be used with caution in patients with Parkinson''s disease and in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.', '2', '', 'DDInter', 0);
